scholarly journals Effect of doxepin on quality of life in Labradors with laryngeal paralysis: A double‐blinded, randomized, placebo‐controlled trial

2021 ◽  
Author(s):  
Mark Rishniw ◽  
Jill Sammarco ◽  
Eric N. Glass ◽  
Brittany Cerroni
Keyword(s):  
Quality Of Life ◽  
Controlled Trial ◽  
Laryngeal Paralysis ◽  
Double Blinded

scholarly journals Effect of low-level laser therapy on pain, quality of life and sleep in patients with fibromyalgia: study protocol for a double-blinded randomized controlled trial

Trials ◽  
2012 ◽  
Vol 13 (1) ◽  
Author(s):  
Paulo de Tarso Camillo de Carvalho ◽  
Ernesto Cesar Pinto Leal-Junior ◽  
Ana Carolina Araruna Alves ◽  
Caroline Sobral de Melo Rambo ◽  
Luciana Maria Malosa Sampaio ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Randomized Controlled Trial ◽  
Laser Therapy ◽  
Study Protocol ◽  
Controlled Trial ◽  
Low Level Laser Therapy ◽  
Randomized Controlled ◽  
Level Laser ◽  
Double Blinded

scholarly journals Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled Trial

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Afsoon Emami Naini ◽  
Mahnaz Moradi ◽  
Mojgan Mortazavi ◽  
Asghar Amini Harandi ◽  
Mehdi Hadizadeh ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Renal Disease ◽  
Chronic Renal Disease ◽  
Controlled Trial ◽  
The Body ◽  
Maintenance Hemodialysis ◽  
Carnitine Supplementation ◽  
Double Blinded ◽  
Esrd Patients

In patients on maintenance hemodialysis several factors reduce the body stored carnitine which could lead to dyslipidemia, anemia, and general health in these patients. We evaluated the effect of oral L-carnitine supplementation on lipid profiles, anemia, and quality of life (QOL) in hemodialysis patients. In a randomized, double-blinded, placebo-controlled trial, end-stage renal disease (ESRD) patients on hemodialysis received either L-carnitine 1 g/d (n=24) or placebo (27 patients) for 16 weeks. At the end of the study, there was a significant decrease in triglyceride (-31.1±38.7 mg/dL,P=0.001) and a significant increase in HDL (3.7±2.8 mg/dL,P<0.001) levels in the carnitine group. Decrease in total cholesterol (−6.6±16.0 mg/dL,P=0.075) and increase in hemoglobin (0.7±1.7 g/dL,P=0.081) concentrations in the carnitine group were not significant. There was no statistically significant changes in LDL in any group (P>0.05). Erythropoietin dose was significantly decreased in both the carnitine (-4750±5772 mg,P=0.001) and the placebo group (-2000±4296 mg,P<0.05). No improvement was observed in QOL scores of two groups. In ESRD patients under maintenance hemodialysis, oral L-carnitine supplementation may reduce triglyceride and cholesterol and increase HDL and hemoglobin and subsequently reduce needed erythropoietin dose without effect on QOL.

Sign in / Sign up

Export Citation Format

Share Document